Department News
The Department of Medical Oncology at Thomas Jefferson University continues to advance cancer care through research, clinical trials, education, and collaboration. Our faculty bring together expertise across solid tumors, hematologic malignancies, melanoma, cellular therapy, and supportive oncology.
Jefferson investigators are exploring new approaches to cancer treatment, including targeted therapies, immunotherapy, cellular therapy, and novel treatment combinations. Recent research in acute myeloid leukemia and melanoma highlights our commitment to translating laboratory discoveries into new treatment options for patients.
Clinical trials are central to our mission. Faculty participate in studies evaluating emerging therapies, diagnostics, and treatment strategies, including early phase and first in human studies. These opportunities allow patients access to innovative treatments while providing valuable experience for our trainees and investigators.
Our faculty continue to expand research in melanoma, multiple myeloma, leukemia, lymphoma, and other complex cancers. Areas of investigation include immunotherapy, cancer vaccines, transplantation, cellular therapy, and strategies to overcome treatment resistance.
Education remains a core component of Medical Oncology. Through fellowship training, research opportunities, clinical experiences, and collaboration with multidisciplinary teams, we prepare the next generation of oncology leaders.
Medical Oncology at Jefferson is focused on improving cancer care today while developing the treatments and discoveries that will shape tomorrow.
Discovery. Innovation. Collaboration. Patient Care.
We would like to welcome Dr, Tara Rakiewicz to The Department of Medical Oncology. Her clinical and research interests focus on the care of patients with hematologic malignancies, with a particular emphasis on multiple myeloma and plasma cell disorders. Her work is dedicated to improving patient outcomes through evidence based treatment strategies, multidisciplinary care, and the integration of emerging therapies into clinical practice.